Provention bio reports third quarter 2022 financial results and provides business update

Continues to advance preparations for potential u.s. commercial launch of teplizumab ahead of november 17 th fda user fee goal date red bank, n.j. , nov. 3, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the third quarter ended september 30, 2022 and provided a business update.
PRVB Ratings Summary
PRVB Quant Ranking